Plant ID: NPO12730
Plant Latin Name: Heracleum maximum
Taxonomy Genus: Heracleum
Taxonomy Family: Apiaceae
NCBI TaxonomyDB:
40918
Plant-of-the-World-Online:
n.a.
India
TSHR; | |
ACHE; | |
HSD17B10; | |
NFKB1; | |
MAPT; LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.532E-13 | 1.858E-08 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.697E-12 | 6.203E-08 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.811E-11 | 1.530E-07 | CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 5.286E-09 | 1.918E-05 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.379E-09 | 2.281E-05 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.626E-08 | 3.511E-05 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.014E-08 | 5.469E-05 | CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 9.302E-08 | 1.447E-04 | CYP2A6, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.425E-07 | 2.068E-04 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.817E-07 | 2.322E-04 | CYP2A6, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 3.678E-07 | 3.482E-04 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 8.842E-07 | 7.702E-04 | CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.768E-06 | 1.283E-03 | CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 6.182E-06 | 3.542E-03 | CYP2A6, CYP2D6 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.323E-05 | 7.205E-03 | CYP2C19, CYP2C9 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 8.853E-05 | 4.284E-02 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.917E-10 | 1.438E-08 | CYP2C9, CYP2A6, CYP2D6, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.286E-08 | 1.982E-06 | CYP2C9, CYP2A6, CYP2D6, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.473E-08 | 2.118E-06 | CYP2C9, CYP2A6, CYP3A4, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 4.487E-07 | 8.414E-06 | CYP2C9, CYP3A4, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 5.306E-06 | 7.960E-05 | CYP2C9, CYP2A6, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.730E-05 | 3.413E-04 | CYP2C9, CYP2D6, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 3.052E-04 | 2.861E-03 | CYP2C9, CYP2A6, CYP2C19, CYP3A4, HSD17B10 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 2.809E-04 | 2.861E-03 | CYP2A6, CYP3A4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.108E-04 | 4.256E-03 | CYP2C9, CYP2C19 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.567E-03 | 1.873E-02 | LMNA, NFKB1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |